Burt Malkiel
Profile
Burton Gordon Malkiel was the founder of AlphaShares LLC, founded in 2007, where the title held was Chief Investment Officer.
Dr. Malkiel was the founder of Baochuan Capital Management LLC, founded in 2010, where the title held was Chairman.
Current jobs include Director at American Philosophical Society, Director at Genmab, Inc., Director at The Maldeb Foundation, Inc. since 2013, Professor-Economics at Princeton University since 1988, Member-Trustee Board at Corvina Foundation, Inc. since 2012, Chief Investment Officer at Wealthfront Corp.
since 2012, and Chief Investment Officer at Wealthfront Advisers LLC since 2012.
Former jobs include Director at BKF Capital Group, Inc., Director at The Vanguard Group, Inc., Independent Director at Genmab A from 2014 to 2018, Independent Director at Innoviva, Inc. from 2011 to 2014, Independent Director at Theravance Biopharma, Inc. from 2013 to 2024, Member at Council of Economic Advisers, President at American Finance Association, Officer at United States Army Finance Corps, Investment Banker at Smith Barney & Co., Inc., President at International Atlantic Economic Society, and Dean at Yale School of Management in 1988.
Education includes undergraduate degree from Harvard University in 1953, doctorate from Princeton University in 1964, and MBAistration from Harvard Business School.
Burt Malkiel active positions
| Companies | Position | Start |
|---|---|---|
| WEALTHFRONT CORPORATION | Corporate Officer/Principal | 01/11/2012 |
Wealthfront Advisers LLC
Wealthfront Advisers LLC Wealthfront Advisers provides clients with investment advice that is based on Modern Portfolio Theory (MPT) which seeks to achieve maximum long-term, risk-adjusted, after-tax, net of fee returns. The firm creates an individualized investment plan using the optimal asset classes in which to invest, the most efficient and inexpensive ETFs to represent each of those asset classes, and the ideal mix of asset classes based on the client’s specific risk tolerance. They adhere to a long-term, “buy-and-hold” investment philosophy. | Chief Investment Officer | 01/11/2012 |
American Philosophical Society
American Philosophical Society Miscellaneous Commercial ServicesCommercial Services Operates scholarly organization that promotes knowledge in the sciences and humanities | Director/Board Member | - |
The Maldeb Foundation, Inc. | Director/Board Member | - |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Creates and develops human antibodies for the treatment of life-threatening and debilitating diseases | Director/Board Member | - |
Corvina Foundation, Inc. | Director/Board Member | 22/02/2012 |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/1988 |
Former positions of Burt Malkiel
| Companies | Position | End |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Director/Board Member | 08/05/2024 |
| GENMAB A/S | Director/Board Member | 01/06/2018 |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Burt Malkiel
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 22 |
|---|---|
BKF Capital Group, Inc.
BKF Capital Group, Inc. Financial ConglomeratesFinance Operates as a holding company which invests in technology companies through its subsidiary | Finance |
The Vanguard Group, Inc.
The Vanguard Group, Inc. Investment ManagersFinance VGI offers both passive and active discretionary investment advisory services that cover the US and international markets. They employ two types of indexing strategies: replication and sampling. Their active management equity methodology is based on quantitative modeling while fixed income analysis is based on fundamental investment research and research obtained from external investment organizations. | Finance |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genmab A/S
Genmab A/S Pharmaceuticals: MajorHealth Technology Develops differentiated antibody therapeutics for treatment of cancer | Health Technology |
Innoviva, Inc.
Innoviva, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that manufactures respiratory drugs | Health Technology |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Council of Economic Advisers
Council of Economic Advisers General GovernmentGovernment Provides economic advices to the President | Government |
American Philosophical Society
American Philosophical Society Miscellaneous Commercial ServicesCommercial Services Operates scholarly organization that promotes knowledge in the sciences and humanities | Commercial Services |
American Finance Association | |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Creates and develops human antibodies for the treatment of life-threatening and debilitating diseases | Commercial Services |
Corvina Foundation, Inc. | |
AlphaShares LLC
AlphaShares LLC Financial ConglomeratesFinance Provides investment services | Finance |
United States Army Finance Corps
United States Army Finance Corps General GovernmentGovernment Engages in financial operations of payroll and contracting | Government |
Smith Barney & Co., Inc.
Smith Barney & Co., Inc. Investment Banks/BrokersFinance Provides securities brokerage services | Finance |
Wealthfront Corp.
Wealthfront Corp. Packaged SoftwareTechnology Services Develops investment platform | Technology Services |
International Atlantic Economic Society
International Atlantic Economic Society Miscellaneous Commercial ServicesCommercial Services The International Atlantic Economic Society is a forum for economists that has been providing a platform for scholarly ideas and intellectual dialogue for over 35 years. The company supports the exchange of ideas and communication worldwide through various venues. The society also awards outstanding undergraduate work in economics and promotes economic research and related activities. The company has awarded over $75,000 in grants and scholarships over the past eight years. The company is based in Atlanta, GA. | Commercial Services |
The Maldeb Foundation, Inc. | |
Baochuan Capital Management LLC
Baochuan Capital Management LLC Baochuan Capital Management (BaoCap) employs a variety of analytical models in formulating investment strategies and managing accounts. Among others, the firm uses fundamental analysis, technical analysis, quantitative analysis and cyclical analysis. BaoCap analyzes the underlying value of a company that issues securities by examining financial statements, price/earnings ratio, competitiveness, management, revenue, relevant markets and competitors of the issuing company. They also examine historical price patterns and trading behavior and monitor current market trends and sentiments as indicated by price movements. BaoCap currently offers clients a number of investment strategies available in different investment products. Their main strategies include the Green Dragon Strategy and the Black Dragon Strategy. In managing the Green Dragon Strategy, BaoCap applies a buy-write strategy to the Chinese equity markets. Specifically, they seek to buy a diversified portfolio of Chinese equities (the Long Portfolio), while managing risk by systematically selling call options on Chinese equity indices that the investment manager believes to have a high correlation with the Long Portfolio (the Short Portfolio). The Long Portfolio typically consists of 25 to 100 of the largest Chinese companies listed on major international exchanges and available to non-Chinese investors. The Long Portfolio largely includes shares of Chinese companies that trade on the Hong Kong Stock Exchange (i.e., HShares or Red Chips) and on the NYSE or NASDAQ (i.e., N-Shares). However, the Long Portfolio may include shares of Chinese companies that trade on other stock exchanges. At this time, the Long Portfolio does not include shares that trade on Chinese exchanges in Shanghai or Shenzhen (i.e., A-Shares or B-Shares). BaoCap attempts to select and weigh the Long Portfolio to provide broad diversification with respect to the Chinese equity markets and high correlation with a basket of Chinese indices that have tradable and liquid options markets. The Short Portfolio strategy is designed to generate income, enhance returns and reduce risk by systematically selling a succession of near-term (generally within one to three months) at-the-money or slightly out-of-the-money call options on Chinese equity indices and/or securities based on such indices. The notional value of the Short Portfolio will be equal to roughly 100% of the Long Portfolio. Because Chinese equity markets are extremely volatile, the premiums received from selling such options are higher than the premiums that might be received from selling call options on more developed markets such as those in the US. In managing the Black Dragon Strategy, the firm seeks to purchase a long portfolio of high quality Chinese companies when they are available at prices they believe are undervalued. They may also opportunistically sell short other Chinese equities they believe are overvalued. The portfolio typically consists of 1 to 20 Chinese companies listed on major international exchanges and available to non-Chinese investors. The portfolio largely includes shares of Chinese companies that trade on the Hong Kong Exchange (i.e., H-Shares or Red Chips) and on the NYSE or NASDAQ (i.e., N-Shares). The portfolio may include shares of Chinese companies that trade on other stock exchanges. At this time, the portfolio does not include shares that trade on Chinese exchanges in Shanghai or Shenzhen (i.e., A-Shares or B-Shares). The portfolio may also include non-Chinese companies that have business dealings in and with China, including but not limited to companies domiciled in Hong Kong, Macao and Taiwan. In managing the Red Dragon Strategy, BaoCap applies quantitative investment strategies to the Chinese equity markets. The firm seeks to buy a broadly diversified portfolio of Chinese equities while typically overweighting, relative to major China equity benchmarks, those Chinese companies that are smaller and/or less expensive using traditional valuation metrics. The Portfolio typically consists of 100 or more Chinese companies listed on major international exchanges and available to non-Chinese investors and those foreign investors without a quota of qualified foreign institutional investors (i.e., QFII quota). The Portfolio largely includes shares of Chinese companies that trade on the Hong Kong Exchange (i.e., H-Shares or Red Chips) and on the New York Stock Exchange or NASDAQ Stock Market (i.e., N-Shares). The Portfolio may include shares of Chinese companies that trade on other stock exchanges. At this time, the Portfolio does not include shares that trade on Chinese exchanges in Shanghai or Shenzhen (i.e., A-Shares or B-Shares). BaoCap typically overweights those stocks that have smaller market capitalizations and/or those that are less expensive when measured by traditional valuation metrics (Price to Earnings, Price to Book Value, Price to Sales, etc.). The investment manager expects the portfolio to have lower than average turnover. The China Century Strategy seeks to achieve its investment objective by pursuing its strategy of investing in a diversified portfolio of securities of Chinese companies and China-linked companies and at least 50% of its investable assets to direct China investment through the funds China Equities Strategy and China Real-Estate Strategy, both as described below, and allocates up to 50% of its investable assets to investment to China-linked companies through the funds China-linked US Equities Strategy and China-linked International Equities Strategy. BaoCap's Global Equities Strategy consists of a combination of the China-Linked US Equities Strategy and the China-Linked International Equities Strategy. The China-Linked US Equities Strategy consists of equity securities of US issuers selected by the firm from a universe of companies with significant exposure to China. BaoCap selects companies they expect to benefit from their exposure to China. The China-Linked International Equities Strategy consists of equity securities of non-US issuers selected from a universe of companies with significant exposure to China. The investment manager selects companies that it expects to benefit from their exposure to China. In addition, BaoCap may invest in high quality US or non-US fixed-income securities, money market instruments, and money market mutual funds, or hold cash or cash equivalents. BaoCap may also invest in money market instruments issued by non-US banks. | |
Theravance Biopharma, Inc.
Theravance Biopharma, Inc. Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | |
Harvard Business School
Harvard Business School Functions as a College/University | |
Yale School of Management
Yale School of Management Functions as a College/University | |
Wealthfront Advisers LLC
Wealthfront Advisers LLC Wealthfront Advisers provides clients with investment advice that is based on Modern Portfolio Theory (MPT) which seeks to achieve maximum long-term, risk-adjusted, after-tax, net of fee returns. The firm creates an individualized investment plan using the optimal asset classes in which to invest, the most efficient and inexpensive ETFs to represent each of those asset classes, and the ideal mix of asset classes based on the client’s specific risk tolerance. They adhere to a long-term, “buy-and-hold” investment philosophy. |
- Stock Market
- Insiders
- Burt Malkiel
















